STING1 and focal segmental glomerulosclerosis: Additionally, CXA-10, a STING inhibitor, has also entered clinical trials as an oral peroxisome proliferator-activated receptor agonist (PPAR) for the treatment of primary focal segmental glomerulosclerosis (FSGS) (Hansen et al., 2018).